Hemodiyalizde Görülen Enfeksiyonlarda Kanıta Dayalı Tedavi Bakım Uygulamaları
Özet
Hemodiyaliz (HD) hastalarında, hem son dönem böbrek yetmezliği (SDBY) nedeniyle bağışıklığın azalmasına bağlı olarak enfeksiyon hastalıkları, hem de HD tedavisi kaynaklı kan yoluyla bulaşan enfeksiyon hastalıklarının görülme sıklığı artmaktadır. HD tedavisi alan hastalarda; hepatit B, hepatit C, HIV, pnömoni, tüberküloz gibi hastalıklar toplum popülasyonuna göre daha fazla görülmektedir. Bu hastalıklar morbidite ve mortalite düzeyini artırmaktadır. Bu nedenle bu hasta popülasyonunda enfeksiyonlardan korunma hayati önem taşır. HD hastalarında enfeksiyon kontrolü, bulaşıcı hastalıkların önlenmesi ve yönetimi için kanıta dayalı uygulamaların kullanılması oldukça önemlidir. Bu bölümde HD hastalarının karşılaşabilecekleri enfeksiyon hastalıklarına karşı kanıta dayalı önlem, tedavi, bakım ve yaklaşımlar yer almaktadır.
Referanslar
Lee JJ, Chang JM, Yang LJ, et al. Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: A nationwide survey in 2010–2018. Journal of the Formosan Medical Association. 2022;121(100):S73–81. Available from: https://doi.org/10.1016/j.jfma.2021.12.019
Abbasi SH, Aftab RA, Mei Lai PS, et al. Prevalence, Microbial Etiology and Risk Factors Associated With Healthcare Associated Infections Among End Stage Renal Disease Patients on Renal Replacement Therapy. Journal of Pharmacy Practice. 2023;36(5):1142–1155.
Fletcher BR, Damery S, Aiyegbusi OL, et al. Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis. PLoS Medicine. 2022;19(4):1–25. Available from: http://dx.doi.org/10.1371/journal.pmed.1003954
Ateş K, Seyahi N, Koçyiğit İ. Türkiye’de nefroloji, diyaliz ve transplantasyon-Registry 2022. Türk Nefroloji Derneği Yayınları. 2023.
Adane T, Getawa S. The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis. PLoS One. 2021;16(6 June):1–17. Available from: http://dx.doi.org/10.1371/journal.pone.0251570
Greeviroj P, Lertussavavivat T, Thongsricome T, et al. The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis. Journal of Nephrology. 2022;35(9):2269–2282. Available from: https://doi.org/10.1007/s40620-022-01483-x
Ji DZ, Pang XY, Shen DT,et al. Global prevalence of occult hepatitis B: A systematic review and meta-analysis. Journal of Viral Hepatitis. 2022;29(5):317–329.
Khalesi Z, Razizadeh MH, Javadi M, et al. Global epidemiology of HBV infection among hemodialysis patients: A systematic review and meta-analysis. Microbial Pathogenesis. 2023;179(January):106080. Available from: https://doi.org/10.1016/j.micpath.2023.106080
Hsu PY, Wei YJ, Liang PC, et al. Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. Journal of Gastroenterology and Hepatology. 2021;36(8):2261–2269.
Saraceni C, Birk J. A review of hepatitis b virus and hepatitis c virus immunopathogenesis. Journal of Clinical Translational Hepatology. 2021;9(3):409–418.
Alcalde-Bezhold G, Alcázar-Arroyo R, Angoso-de-Guzmán M, et al. Hemodialysis Centers Guide 2020. Nefrologia. 2021;41:1–77.
Girndt M, Plüer M, Dellanna F, et al. Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seropro. Human Vaccines Immunotherapeutics. 2022;18(6). Available from: https://doi.org/10.1080/21645515.2022.2136912
Udomkarnjananun S, Takkavatakarn K, Praditpornsilpa K, et al. Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis. Journal of Nephrology. 2020;33(2):343–354. Available from: https://doi.org/10.1007/s40620-019-00668-1
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.
Yao T, Shao Z, Wu L, et al. Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: A 3-year follow-up study in China. Vaccine. 2021;39(18):2537–2544. Available from: https://doi.org/10.1016/j.vaccine.2021.03.074
Bozaci I, Tosun S. The relationship of hepatits b core antibody positivity with demographic and laboratory parameters in hemodialysis patients. Haseki Tip Bulteni. 2021;59(3):255–260.
Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology. 2017;67(2):370–398.
Akarca U, Baykam N, Güner R, Günşar F, İdilman R, Karasu Z, et al. Türkiye Hepatit B Tanı ve Tedavi Kılavuzu. 2023. 1–30 p.
Xun Z, Fu Y, Ye YC, et al. Discussion on the guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Zhonghua Gan Zang Bing Za Zhi. 2023;31(10):1099–1100.
Hsu YC, Wong GLH, Chen CH, et al. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. The American Journal of Gastroenterology. 2020;115(2):271–280.
Chon HY, Ahn SH, Kim YJ, et al. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. Hepatol International 2021;15(6):1328–1336. Available from: https://doi.org/10.1007/s12072-021-10262-y
Kenfack-Momo R, Ngounoue MD, Kenmoe S, et al. Global epidemiology of hepatitis C virus in dialysis patients: A systematic review and meta-analysis. PLoS One. 2024;19(2 February):1–15.
Goodkin DA, Bieber B, Jadoul M, et al. Mortality, hospitalization, and quality of life among patients with hepatitis c infection on hemodialysis. Clinical Journal of the American Society of Nephrology. 2017;12(2):287–297.
Martin P, Awan AA, Berenguer MC, et al. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney International. 2022;102(6):1228–1237.
Prabhu AR, Rao IR, Nagaraju SP, et al. Interventions for dialysis patients with hepatitis C virus (HCV) infection. Cochrane Database. 2023;2023(4).
Marc L, Mihaescu A, Lupusoru R, et al. Hepatitis C and hepatitis B virus infection in hemodialysis patients after nationwide direct antiviral agents therapy—experience of 10 Romanian HD centers. International Urology and Nephrology 2023;55(11):2951–2958. Available from: https://doi.org/10.1007/s11255-023-03587-0
Akarca U, Baykam N, Güner R, Günşar F, İdilman R, Karasu Z, et al. Türkiye Hepatit C Tanı ve Tedavi Kılavuzu. 2023.
Eknoyan G, Lameire N, Kasiske B. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney International Supplements. 2018;8(3):91–165.
Alfano G, Guaraldi G, Fontana F, et al. Therapeutic management of HIV-infected patients with chronic kidney disease. Journal of Nephrology. 2020;33(4):699–713. Available from: https://doi.org/10.1007/s40620-020-00701-8
Valdivia-Cerda V, Alvarez-Zavala M, Sánchez-Reyes K, et al. Prevalence and risk factors of chronic kidney disease in an HIV positive Mexican cohort. BMC Nephrology. 2021;22(1):1–7. Available from: https://doi.org/10.1186/s12882-021-02526-4
Jeyarajan AJ, Chung RT. Insights into the pathophysiology of liver disease in HCV/HIV: Does it end with HCV cure? 2020 The Journal of Infectious Diseases;222(Suppl 9):S802–813.
Reeves I, Cromarty B, Deayton J, et al. British HIV Association guidelines for the management of HIV-2 2021. Vol. 22, HIV Medicine. 2021. 1–29 p.
Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases. 2016;63(5):e61–111.
Alkan Çeviker S, Tahmaz A. Hemodiyaliz Hastalarında Solunum Yolu Enfeksiyonları ve Korunma. Black Sea Journal of Health Science. 2019;2(3):85–89.
Zuo M, Tang J, Xiang M, et al. Characteristics and factors associated with nosocomial pneumonia among patients undergoing continuous renal replacement therapy (CRRT): A case–control study. International Journal of Infectious Diseases. 2018;March(68):115–121.
Carr BZ, Briganti EM, Musemburi J, et al. Effect of chronic kidney disease on all-cause mortality in tuberculosis disease: an Australian cohort study. BMC Infectious Diseases. 2022;22(1):1–8. Available from: https://doi.org/10.1186/s12879-022-07039-5
Alemu A, Bitew ZW, Diriba G, et al. The prevalence of latent tuberculosis infection in patients with chronic kidney disease: A systematic review and meta-analysis. Heliyon. 2023;9(6):e17181. Available from: https://doi.org/10.1016/j.heliyon.2023.e17181
Şenol G. Tüberküloz Enfeksiyonu Hastalığı veTedavisi. In: Parlak M, Işıkgöz Taşbakan M, editors. Bitmeyen Pandemi Tüberküloza Güncel Yaklaşım. 1st ed. Ankara: Bilimsel Tıp Yayınevi; 2023. p. 40–47.
Puspitasari M, Sattwika PD, Rahari DS, et al. Outcomes of vaccinations against respiratory diseases in patients with end-stage renal disease undergoing hemodialysis: A systematic review and meta-analysis. PLoS One. 2023;18(2 February):1–27. Available from: http://dx.doi.org/10.1371/journal.pone.0281160
Ma BM, Yap DYH, Yip TPS, et al. Vaccination in patients with chronic kidney disease—Review of current recommendations and recent advances. Nephrology. 2021;26(1):5–11.
